2023-09-05 11:18:53
Multiple myeloma and acute lymphoblastic leukemia are two blood cancers that together generate more than 4,000 new diagnoses each year in Mexico, according to official data presented Monday by the biotechnology company Amgen, which launched the “Hematological September” campaign with the objective of raising awareness among the population of the country about this type of disease.
A blood test will suffice to detect cancer. EFE/Rodrigo Sura
According to figures from the International Agency for Research on Cancerbelonging to the World Health Organization (WHO)each year there are 176,404 new cases of multiple myeloma and 474,519 of leukemia worldwide, two important blood cancers.
Meanwhile, in Mexico, it is estimated that there are approximately 5,000 people living with multiple myeloma, and about 2,500 new cases each year. In the case of acute lymphoblastic leukemia, each year there are 2,000 new cases in children.
Multiple myeloma
Multiple myeloma, which commemorates its World Day every September 5, is the second most common blood cancer after non-Hodgkin lymphomas. This type of neoplasm causes excessive growth of plasma cells in the bone marrow, which are an important component of the immune system.
This disease can cause anemia, a low level of platelets in the blood (thrombocytopenia), or leukopenia (shortage of normal white blood cells), making it difficult to fight infections.
The main symptoms are bone pain, chest pain, nausea, constipation, loss of appetite, disorientation or mental confusion, fatigue, frequent infections, weight loss, weakness or numbness in the legs, and excessive thirst.
“Thanks to advances in medical research, there are currently innovative drugs that help modify the natural course of this disease, offering a better quality of life to people who suffer from it,” Amgen Mexico medical director Max said in a statement. Sarachaga.
lymphoblastic leukemia
Meanwhile, acute lymphoblastic leukemia represents 50% of all cases of childhood cancer in Mexico. This type of cancer begins in the early version of white blood cells, or lymphocytes, in the bone marrow.
Some of the symptoms are recurrent or acute infections, paleness and tiredness, anemia, frequent bleeding from the nose or gums, and bruising.
This disease usually progresses quickly, so timely diagnosis and the beginning of treatment are determinant to improve the prognosis of recovery.
At the moment, patient survival has increased significantly thanks to therapies based on T-cell specific monoclonal antibodies.
This treatment, approved by the Food and Drug Administration (FDA, for its acronym in English) of the United States, fights cancer by helping the immune system to detect and attack malignant cells through T cells (a type of white blood cell capable of killing other cells perceived as threats).
Extraction of blood for treatments during bone marrow transplantation. EFE/Rungroj Yongrit
Primary immune thrombocytopenia
Other A little-known bleeding disorder that Amgen’s campaign aims to raise awareness about is Primary Immune Thrombocytopenia (PIT), what affects the ability of blood to clot due to too low a number of blood cells called platelets.
This disease, which mainly affects adults, May cause bleeding under the skin or from injury and damage to blood vesselss and among its symptoms are bruises and bleeding that look like red dots.
Given this, Amgen will continue to develop and research new therapies to treat serious diseases and significantly improve people’s quality of life through biotechnology, according to the statement.
#cases #year #Mexico